Author:
Al Aufi Ahmed,Stephen Edwin,Al Lawati Ali,Abdelhady Ibrahim,Al Maawali Hanan,Al Wahaibi Khalifa
Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Erfurt-Berge C, Renner R (2008) Management of patients with calciphylaxis: current perspectives. J Clin Aesthet Dermatol 1(2):38–41
2. Nunley R, Calciphylaxis. Medscape. available from https://emedicine.medscape.com/article/1095481-overview, accessed on 07/04/2020.
3. Hanafusa T, Yamaguchi Y, Tani M, Umegaki N, Nishimura Y, Katayama I (2007) Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. J Am Acad Dermatol 57(6):1021–1025
4. Chen T, Lehman J, Gibson L, Lohse C, El-Azhary R (2017) Histopathology of calciphylaxis. Am J Dermatopathol 39(11):795–802
5. Price P, Faus S, Williamson M (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21(5):817–824